logo
  

Aligos Therapeutics Prices IPO Of 10 Mln Shares At $15/Shr

Aligos Therapeutics, Inc. announced that it has priced initial public offering of 10 million common shares at $15.00 per share, the midpoint of the range between $14.00 and $16.00 per share. The offering is expected to close on October 20, 2020.

In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock at the initial public offering price.

The company sees offering gross proceeds, before expenses, to be about $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares.

Aligos' common stock began trading on the Nasdaq Global Select Market on October 16, 2020, under the ticker symbol "ALGS."

J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional... Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton.
Follow RTT